The shares of Novavax Inc. (Nasdaq: NVAX) hogged the limelight on Friday following the news of signing a $1.40 billion agreement with France-headquartered pharmaceutical company Sanofi. According to the agreement, Sanofi will co-commercialize the biotech firm’s COVID-19 drug beginning next year.
Additionally, both pharmaceutical firms will collaborate on the development of combo shots aimed at the flu and coronavirus, among other initiatives. The stock of Novavax ended Friday’s trading session at $6.40, up $1.93, or 43.18%, from the prior close.
The licensing deal represents a significant milestone for Novavax, headquartered in Gaithersburg, Maryland. This agreement will enable Novavax to remove its “going concern” caution, initially released in February 2023 due to uncertainties associated with its operational continuity, stated Novavax CEO John Jacobs.
This development signifies a crucial moment for the vaccine manufacturer, particularly concerning its protein-based COVID shot. Health authorities recognize the vaccine as a crucial substitute for individuals reluctant to receive messenger RNA vaccines from both Moderna and Pfizer.
As per the deal, Sanofi will get access to the Covid-19 vaccine developed by Novavax, along with the proven vaccine technology, referred to as Matrix-M adjuvant, for developing a new range of vaccines. In return, Novavax will get $500 million as an advance payment from Sanofi. Additionally, Novavax will also be paid a maximum of $700 million for several development, rollout, and legislative milestones. Notably, the deal effectively pays almost double the $627 million market cap of Novavax.
Additionally, Novavax will also receive royalty payments pertaining to the sales of Covid drugs and combo shots aimed at flu and coronavirus from Sanofi. The agreement entitles Novavax to receive a maximum of $200 million in payments related to new launches, sales milestones, and royalties for any drug developed by Sanofi using the Matrix-M adjuvant technology.
According to the terms of the agreement, Sanofi will acquire a stake of less than 5% in Novavax. Novavax CEO Jacobs expressed optimism about the agreement, highlighting its role in bolstering the company’s financial position, eliminating concerns about continuity, and enabling a strategic shift toward maximizing value for investors.
The agreement aligns with Novavax’s mission of leveraging its vaccine technology framework to enhance international public health, a goal that would be difficult to achieve independently due to resource limitations, capital constraints, and operational scope.
Novavax will head the marketing of its COVID vaccine until the end of this year. At the same time, Novavax will start transferring key responsibilities to Sanofi and will complete the process next year. Sanofi’s contract will not be applicable in countries where Novavax has partnership deals. This includes Japan, India, South Korea, and other countries with forward-looking COVID vaccine purchase deals.
Jacobs emphasized Sanofi’s potential to expand the market share and accessibility of Novavax’s COVID vaccine, thereby broadening patient access.
Through this collaboration with Sanofi, a leader in both commercialization and development, Novavax anticipates accelerated vaccine development and commercialization, facilitating the introduction of several new vaccines expeditiously.
Separately, Novavax plans to commence late-stage piloting for its combination vaccine focused on COVID and the flu, as well as its standalone flu jab, in the months ahead. This trial expansion, enabled by the agreement, enhances Novavax’s pipeline and accelerates the progress of its vaccine development initiatives.
The huge co-commercialization contract is expected to keep the stock of Novavax bullish in the upcoming trading sessions.
The historical price chart indicates that the stock of Novavax has broken above the long-term resistance at $8.50. The MACD indicator is also showing a positive reading. Therefore, we anticipate Novavax’s stock to remain in an uptrend in the near term.
Disclaimer: Any financial trading analysis offered here is our opinion and is not intended as advice or direction for investors. We cannot guarantee the success of any trades made as a consequence of this article, and we encourage traders to incorporate a strong money management strategy to limit losses when they enter the markets. Please use this article as part of your own research before formulating strategies prior to trading.
